• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND RESOLUTE INTEGRITY RX; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND RESOLUTE INTEGRITY RX; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Myocardial Infarction (1969); Thrombus (2101); Stenosis (2263); Injury (2348)
Event Date 10/15/2019
Event Type  Injury  
Manufacturer Narrative
Age: average age.Sex: majority gender.Date of event: date of publication journal article title: percutaneous treatment and outcomes of small coronary vessels literature reference: doi.Org/10.1016/j.Jcin.2019.10.062.If information is provided in the future, a supplemental report will be issued.
 
Event Description
The aim of this study was to compare the treatment outcomes of patients with de novo lesions in small coronary vessels undergoing percutaneous coronary intervention (pci) in sweden from april 2009 to july 2017 with drug-coated balloons (dcbs) or newer-generation drug-eluting stents (n-des).The in.Pact falcon was one brand of dcb used to treat patients in the dcb group within the study population.Patients included in the comparator n-des group were implanted with endeavor resolute, resolute integrity, and resolute onyx stents as well as the old-generation endeavor zotarolimus-eluting stent.A number of non-medtronic stents were also implanted in patients within this n-des group.14,788 patients with small-vessel cad were enrolled in the study: 1,154 were treated with dcbs and 13,634 with n-des.Altogether, 35,541 lesions were treated using 2,503 dcbs and 33,038 n-des.At a 3 year follow up, patients were assessed for the occurrence in the primary outcomes of restenosis and definite target lesion thrombosis and in secondary outcomes of all-cause death and myocardial infarction.Clinical outcomes reported in the study population included death, myocardial infarction, target lesion thrombosis, and restenosis.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESOLUTE INTEGRITY RX
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
IE 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
IE  
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
IE  
091708734
MDR Report Key9984932
MDR Text Key196912918
Report Number9612164-2020-01633
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeSW
PMA/PMN Number
P110013
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 04/22/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/22/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received04/15/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age69 YR
-
-